Podstawowe statystyki
| LEI | 549300JETJBH94EIPC66 |
| CIK | 1666071 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cardlytics, Inc.
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 CARDLYTICS, INC. |
|
| June 3, 2026 |
CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CARDLYTICS, INC. |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 CARDLYTICS, INC. |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2026 CARDLYTICS, INC. |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 CARDLYTICS, INC. |
|
| May 7, 2026 |
Exhibit 10.3 Amit, On behalf of the Compensation Committee and the Board, I want to personally recognize the critical role you’ve played in advancing the Bridg transaction. In recognition of your impact and the importance of this milestone for the Company, the Compensation Committee has approved a $100,000 transaction bonus. This bonus will be paid following the successful close of the Bridg trans |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| May 7, 2026 |
Cardlytics First Quarter 2026 Financial Results Driven By Strong Operational Performance Exhibit 99.1 Cardlytics First Quarter 2026 Financial Results Driven By Strong Operational Performance •Company delivers strong first quarter results: ◦Revenues from continuing operations $34.3 million; additional $4.2 million from Bridg discontinued operations ◦Billings from continuing operations of $58.1 million; additional $4.2 million from Bridg discontinued operations ◦Adjusted Contribution fr |
|
| May 7, 2026 |
Sixth Amendment to Amended and Restated Loan and Security Agreement Exhibit 10.5 Sixth Amendment to Amended and Restated Loan and Security Agreement Borrower: Cardlytics, Inc., a Delaware corporation Date: April 22, 2026 This SIXTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into among, the Borrower named above (the “Borrower”), the lenders from time to time party to the Loan Agreement (“Lenders”) and Banc of Califor |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTAIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Materials Pursuant to 240. |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 9, 2026 |
cdlxform10-kx2025xfinal UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 24, 2026 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As previously disclosed by Cardlytics, Inc. (the “Company”) on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 26, 2026 (the “Prior Current Report”), on January 23, 2026, the Company, PAR Technology Corporation (“PAR”) and DB Sub, LLC, an indirectly wholly owned subsidiary of |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2026 CARDLYTICS, INC. |
|
| March 4, 2026 |
Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results Exhibit 99.1 Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results Atlanta, GA – March 4, 2026 – Cardlytics, Inc. (NASDAQ: CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, we took several steps to reset our business and improve our financial health,” said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well |
|
| March 4, 2026 |
Non-Employee Director Compensation Policy As Amended & Restated February 17, 2026 Exhibit 10.35 Non-Employee Director Compensation Policy As Amended & Restated February 17, 2026 Each member of the Board of Directors (the “Board”) of Cardlytics, Inc. (the “Company”) who is a non- employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation Polic |
|
| March 4, 2026 |
Exhibit 10.39 SEPARATION PAY AGREEMENT This Separation Pay Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”), and David Evans (“You” or “Your”) (collectively, the “Parties”), is entered into and effective as of January 12, 2025 (the “Effective Date”). WHEREAS, the Company has offered to employ You as the Company’s Chief Financial Officer; WHEREAS, the Company and You have |
|
| March 4, 2026 |
Exhibit 10.37 Execution Version ASSET PURCHASE AGREEMENT among CARDLYTICS, INC., PAR TECHNOLOGY CORPORATION and DB SUB, LLC, dated as of January 23, 2026 Exhibit 10.37 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE 13 Section 2.01 Purchase and Sale of the Purchased Assets 13 Section 2.02 Excluded Assets 15 Section 2.03 Assumed Liabilities 16 Section 2.04 Excluded Liabi |
|
| March 4, 2026 |
Calculation of Filing Fee Tables Calculation of Filing Fee Tables S-8 Cardlytics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, 2018 Employee Stock Purchase Plan Other 500,000 $ 0.7527 $ 376,338.00 0.0 |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| March 4, 2026 |
Exhibit 10.36 2025 Bonus Plan Overview The 2025 Cardlytics Bonus Plan (“Bonus Plan”) outlines the terms for a cash bonus that may be awarded to certain employees for helping Cardlytics, Inc. (“Company”) reach its corporate goals and in recognition of their personal performance during the year. All bonuses earned are paid as lump-sum payments after the conclusion of the 2025 annual review process. |
|
| March 4, 2026 |
As filed with the Securities and Exchange Commission on March 4, 2026 Registration No. |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 CARDLYTICS, INC. |
|
| March 4, 2026 |
List of Subsidiaries of Cardlytics, Inc. Exhibit 21.1 List of Subsidiaries of Cardlytics, Inc. Company Name Jurisdiction Cardlytics UK Limited England and Wales Cardlytics Services India Private Limited India |
|
| March 4, 2026 |
Exhibit 10.38 Congratulations, David Evans! We are thrilled about you serving as the Chief Financial Officer of Cardlytics, Inc. (the “Company”) and are excited to present this offer to you. Below you will find details regarding your offer. Position: Chief Financial Officer, reporting to the Chief Executive Officer Start Date: January 12, 2026 (the “Start Date”) Annual Base Salary: $400,000, subje |
|
| March 4, 2026 |
Consent and Fifth Amendment to Amended and Restated Loan and Security Agreement Exhibit 10.40 Consent and Fifth Amendment to Amended and Restated Loan and Security Agreement Borrower: Cardlytics, Inc., a Delaware corporation Date: February 12, 2026 This CONSENT AND FIFTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into among, the Borrower named above (the “Borrower”), the lenders from time to time party to the Loan Agreement (“L |
|
| January 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2026 CARDLYTICS, INC. |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 CARDLYTICS, INC. |
|
| December 18, 2025 |
Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer ATLANTA, December 18, 2025 – Cardlytics Inc. |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 CARDLYTICS, INC. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 CARDLYTICS, INC. |
|
| November 5, 2025 |
Cardlytics Announces Third Quarter 2025 Financial Results Exhibit 99.1 Cardlytics Announces Third Quarter 2025 Financial Results Atlanta, GA – November 5, 2025 – Cardlytics, Inc. (NASDAQ: CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to |
|
| October 2, 2025 |
144 0001961238 XXXXXXXX LIVE 0001666071 Cardlytics, Inc. 001-38386 675 PONCE DE LEON AVENUE, NE SUITE 4100 ATLANTA GA 30308 888-798-5802 Gupta Amit Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 7799 17710.75 53236901 10/02/2025 NASDAQ Common 10/01/2025 Restricted Stock Vesting Issuer N 7799 10/01/2025 Compensation N Amit Gupta 675 Ponce de Leon Ave. N |
|
| October 2, 2025 |
Cardlytics Announces Workforce Reductions As Part Of Organizational Realignment and Cost Savings Initiative Atlanta, GA – October 2, 2025 – Cardlytics Inc. |
|
| October 2, 2025 |
144 0001987391 XXXXXXXX LIVE 0001666071 Cardlytics, Inc. 001-38386 675 PONCE DE LEON AVENUE, NE SUITE 4100 ATLANTA GA 30308 888-798-5802 DeSieno Alexis Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 8493 19286.75 53236901 10/02/2025 NASDAQ Common 10/01/2025 Restricted Stock Vesting Issuer N 8493 10/01/2025 Compensation N Alexis R. Desieno 675 Ponce de Leon Ave. |
|
| October 2, 2025 |
144 0001941467 XXXXXXXX LIVE 0001666071 Cardlytics, Inc. 001-38386 675 PONCE DE LEON AVENUE, NE SUITE 4100 ATLANTA GA 30308 888-798-5802 Lynton Nicholas Hollmeyer Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 6098 13847.95 53236901 10/02/2025 NASDAQ Common 10/01/2025 Restricted Stock Vesting Issuer N 6098 10/01/2025 Compensation N Nicholas H. Lynton 675 Ponce |
|
| October 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2025 CARDLYTICS, INC. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| August 6, 2025 |
Amended Offer Letter between Amit Gupta and the Registrant, dated June 23, 2025. Exhibit 10.3 Congratulations, Amit Gupta! We are thrilled about you serving as the Chief Executive Officer of Cardlytics and are excited to present this offer to you, as amended and restated on June 23, 2025. Below you will find details regarding your offer. Position: Chief Executive Officer, reporting to the Company’s Board of Directors (the “Board”) Start Date: August 16, 2024 (the “Start Date”) |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 CARDLYTICS, INC. |
|
| August 6, 2025 |
Exhibit 10.5 FOURTH AMENDMENT TO SCHEDULE #1 This Fourth Amendment (“Amendment”) to that certain Schedule #1 dated May 4, 2018 (“Schedule”), as amended on October 23, 2018, June 4, 2020, and June 1, 2023, is made effective on July 7, 2025 (the “Amendment Effective Date”) between JPMORGAN CHASE BANK, NATIONAL ASSOCIATION (“JPMC”) and CARDLYTICS, INC. (“Supplier”). NOW, THEREFORE, in consideration o |
|
| August 6, 2025 |
Amended Separation Pay Agreement between Amit Gupta and the Registrant, dated June, 23, 2025. Exhibit 10.4 AMENDED AND RESTATED SEVERANCE AGREEMENT This Amended and Restated Severance Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”), and Amit Gupta (“You” or “Your”) (collectively, the “Parties”), is entered into and effective as of June 23, 2025 (the “Effective Date”) and amends and restates the Severance Agreement, dated as of January 23, 2023, by and between th |
|
| August 6, 2025 |
Cardlytics Announces Second Quarter 2025 Financial Results Exhibit 99.1 Cardlytics Announces Second Quarter 2025 Financial Results Atlanta, GA – August 6, 2025 – Cardlytics, Inc. (NASDAQ: CDLX), a commerce media platform, today announced financial results for the second quarter ended June 30, 2025. "Building on the progress we've made over the past year, we are navigating headwinds by doubling down on our diversification efforts and reinforcing our unique |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 CARDLYTICS, INC. |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 CARDLYTICS, INC. |
|
| May 20, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 CARDLYTICS, INC. |
|
| May 20, 2025 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share to |
|
| May 20, 2025 |
Exhibit 10.1 Cardlytics, Inc. 2025 Equity Incentive Plan Adopted by the Board of Directors: February 12, 2025 Approved by the Stockholders: May 20, 2025 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Company’s 2018 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the Effective Date, no a |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 Registration No. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 CARDLYTICS, INC. |
|
| May 7, 2025 |
Cardlytics Announces First Quarter 2025 Financial Results Exhibit 99.1 Cardlytics Announces First Quarter 2025 Financial Results Atlanta, GA – May 7, 2025 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| May 7, 2025 |
Exhibit 10.2 Third Amendment to Amended and Restated Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation ("Parent") (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company Date: March 26, 2025 This THIRD AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this "Amendment") is entered into among, the borrowers |
|
| May 7, 2025 |
Exhibit 10.3 Fourth Amendment to Amended and Restated Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company Date: April 16, 2025 This FOURTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into among, the borrowe |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 CARDLYTICS, INC. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTAIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Materials Pursuant to 240. |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 CARDLYTICS, INC. |
|
| March 12, 2025 |
Exhibit 10.38 Second Amendment to Amended and Restated Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company Date: January 27, 2025 This SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into among, the borr |
|
| March 12, 2025 |
Exhibit 19.1 Cardlytics, Inc. Amended and Restated Insider Trading and Window Period Policy Effective as of March 7, 2024 I.Introduction This policy determines acceptable transactions in the securities of Cardlytics, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important informa |
|
| March 12, 2025 |
Exhibit 10.37 First Amendment to Amended and Restated Loan and Security Agreement and Consent Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| March 12, 2025 |
Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results Atlanta, GA – March 12, 2025 – Cardlytics, Inc. (NASDAQ: CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," |
|
| March 12, 2025 |
2024 Bonus Plan of the Registrant Exhibit 10.39 2024 Bonus Plan Overview The 2024 Cardlytics Bonus Plan (“Bonus Plan”) outlines certain cash bonus payouts that may be awarded to certain employees for helping Cardlytics, Inc. (“Company”) reach its corporate goals and in recognition of their personal performance during the year. All bonuses earned are paid as lump-sum payments after the conclusion of the 2024 annual review process. |
|
| January 23, 2025 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Common Stock, par value $0.0001 per share 2018 Equity In |
|
| January 23, 2025 |
As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. |
|
| January 3, 2025 |
Transactions in the Shares of the Issuer During the Past Sixty Days Exhibit 1 Transactions in the Shares of the Issuer During the Past Sixty Days Nature of Transaction Amount of Securities Purchased/(Sold) Price per Share ($) Date of Purchase/Sale SOSIN MASTER, LP Sale of Common Stock (19,523) 3.9530 12/03/2024 Sale of Common Stock (15,650) 3.7784 12/30/2024 Sale of Common Stock (15,650) 3.7661 12/31/2024 |
|
| November 12, 2024 |
CDLX / Cardlytics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us14161w1053111224.txt us14161w1053111224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) CARDLYTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 14161W105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 6, 2024 |
Cardlytics Announces Third Quarter 2024 Financial Results Exhibit 99.1 Cardlytics Announces Third Quarter 2024 Financial Results Atlanta, GA – November 6, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2024. "Our third quarter results beat the high end of our guidance, which reflects our relentless focus on addressing our short-term challenges," said Amit |
|
| November 6, 2024 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate-Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share, 202 |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Exhibit 10.3 Amended and Restated Loan and Security Agreement Borrower: Cardlytics, Inc. Address: 675 Ponce de Leon Ave. NE, Suite 4100, Atlanta, GA 30308 Borrower: Dosh Holdings LLC, an Ohio limited liability company Address: 675 Ponce de Leon Ave. NE, Ste 4100, Atlanta, GA 30308 Borrower: AFIN Intermediate Holdings, Inc. a Delaware corporation Address: 675 Ponce de Leon Ave. NE, Ste 4100, Atlant |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| November 6, 2024 |
Amendment No. 3 to 2022 Inducement Plan Exhibit 4.9 AMENDMENT TO CARDLYTICS, INC. 2022 INDUCEMENT PLAN A. Cardlytics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2022 Inducement Plan (the “Plan”); B. The Plan currently provides for 2,650,000 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now wishes to amend the Plan to increase th |
|
| November 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 CARDLYTICS, INC. |
|
| November 6, 2024 |
Offer Letter between Amit Gupta and the Registrant, dated Exhibit 10.1 Congratulations, Amit Gupta! We are thrilled about you serving as the Chief Executive Officer of Cardlytics and are excited to present this offer to you. Below you will find details regarding your offer. Position: Chief Executive Officer, reporting to the Company’s Board of Directors (the “Board”) Start Date: August 16, 2024 (the “Start Date”) Annual Base Salary: $550,000.00, subject to ap |
|
| November 6, 2024 |
Assumption Agreement and Eighteenth Amendment to Loan and Security Agreement, dated as of Exhibit 10.2 Eighteenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liability |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CARDLYTICS, INC. |
|
| October 24, 2024 |
CDLX / Cardlytics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us14161w1053102424.txt us14161w1053102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) CARDLYTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 14161W105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 CARDLYTICS, INC. |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 CARDLYTICS, INC. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| August 7, 2024 |
Cardlytics Appoints Amit Gupta as CEO Exhibit 99.2 Cardlytics Appoints Amit Gupta as CEO Atlanta, GA – August 7, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced that the Board of Directors has appointed Amit Gupta, Chief Operating Officer and General Manager of Bridg, as its next Chief Executive Officer of Cardlytics, effective August 16, 2024. He will also join the Cardlytics Board of Directors |
|
| August 7, 2024 |
Statement of Work Change Order dated May 24, 2024, between the Registrant and Bank of America, N.A. Exhibit 10.1 Change Order Contract Title: First Change Order Change Order Contract Number: CDR0008840.0 Order Number: CW1813213 Vendor Name: Cardlytics, Inc. 675 Ponce de Leon Ave, Suite 4100 Atlanta, GA 30308 Effective Date: Expiration Date: date of the last signature below 07/31/2025 Main Agreement: CW1649578 - This CHANGE ORDER amends the Order Number identified above, which was executed under |
|
| August 7, 2024 |
Exhibit 10.2 Seventeenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liabilit |
|
| August 7, 2024 |
Cardlytics Announces Second Quarter 2024 Financial Results Exhibit 99.1 Cardlytics Announces Second Quarter 2024 Financial Results Atlanta, GA – August 7, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the second quarter ended June 30, 2024. “We continue to believe in the significant growth opportunity as we invest to modernize our platform. We are making progress, but transitions like this ta |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 14161W105 (CUSIP Number) CLIFFORD SOSIN CAS INVESTMENT |
|
| May 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 CARDLYTICS, INC. |
|
| May 8, 2024 |
Cardlytics Announces First Quarter 2024 Financial Results Exhibit 99.1 Cardlytics Announces First Quarter 2024 Financial Results Atlanta, GA – May 8, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2024. “Our results in the first quarter reflect the progress we have made at delivering more value to both consumers and our advertising partners,” said Karim Temsa |
|
| May 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CARDLYTICS, INC. |
|
| May 8, 2024 |
Exhibit 10.4 Work Order 00011520.0 dated March 14, 2024 to Master Hosted Services Agreement 00006601.0 This Order ("Order") is entered into by and between American Express Travel Related Services Company, Inc. ("AXP") and Cardlytics, Inc. ("Supplier"), as of the date referenced above ("Order Effective Date") pursuant to the Master Hosted Services Agreement by and between AXP and Supplier, dated as |
|
| May 8, 2024 |
Exhibit 10.3 Sixteenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2)Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company (3)AFIN Intermediate Holdings, Inc. a Delaware corporation (4)AFIN Holdings Inc., a Delaware corporation (5)HSP EPI Acquisition, LLC, a Delaware limited liability comp |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTAIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Materials Pursuant to 240. |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 9, 2024 |
Liane Hornsey Appointed to Cardlytics Board of Directors Exhibit 99.1 Liane Hornsey Appointed to Cardlytics Board of Directors ATLANTA, April 8, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, is excited to announce the appointment of Liane Hornsey to its Board of Directors. In connection with her appointment to the Board of Directors, Hornsey was also appointed to the Board’s Compensation Committee, and she will assume the role |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 CARDLYTICS, INC. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 CARDLYTICS, INC. |
|
| April 1, 2024 |
Exhibit 4.1 EXECUTION VERSION ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ CARDLYTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee ───────────────────── INDENTURE Dated as of April 1, 2024 ───────────────────── 4.25% Convertible Senior Notes due 2029 ═══════════════════════════════════════════════════════ ════ |
|
| April 1, 2024 |
Cardlytics Prices $150.0 Million Convertible Senior Notes Offering Exhibit 99.2 Cardlytics Prices $150.0 Million Convertible Senior Notes Offering ATLANTA, March 26, 2024—Cardlytics, Inc. (NASDAQ: CDLX) (“Cardlytics”), an advertising platform in banks’ digital channels, today announced the pricing of its offering of $150.0 million aggregate principal amount of 4.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional b |
|
| April 1, 2024 |
Cardlytics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Cardlytics Announces Proposed Convertible Senior Notes Offering ATLANTA, March 26, 2024— Cardlytics, Inc. (NASDAQ: CDLX) (“Cardlytics”), an advertising platform in banks’ digital channels, today announced its intention to offer, subject to market and other conditions, $150.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to |
|
| March 29, 2024 |
SC 13D/A 1 sc13da31260900203292024.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 CARDLYTICS, INC. |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 14161W105 (CUSIP Number) CLIFFORD SOSIN CAS INVESTMENT |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 CARDLYTICS, INC. |
|
| March 18, 2024 |
Cardlytics, Inc. Up to $50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276738 Prospectus Supplement (To Prospectus dated February 9, 2024) Cardlytics, Inc. Up to $50,000,000 Common Stock We have entered into an equity distribution agreement (the “Equity Distribution Agreement”), dated as of March 18, 2024, with Evercore Group L.L.C., BofA Securities, Inc. and Cantor Fitzgerald & Co. as sales agen |
|
| March 18, 2024 |
Exhibit 1.1 CARDLYTICS, INC. Common Stock (par value $0.0001 per share) Having an Aggregate Offering Price of Up to $50,000,000 Equity Distribution Agreement March 18, 2024 Evercore Group L.L.C. 55 East 52nd Street, 36th Floor New York, New York 10055 BofA Securities, Inc. One Bryant Park New York, New York 10036 Cantor Fitzgerald & Co. 110 East 59th Street New York, New York 10022 Ladies and Gent |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 CARDLYTICS, INC. |
|
| March 14, 2024 |
Exhibit 10.49 Consent and Fourteenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2)Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company (3)AFIN Intermediate Holdings, Inc. a Delaware corporation (4)AFIN Holdings Inc., a Delaware corporation (5)HSP EPI Acquisition, LLC, a Delaware limit |
|
| March 14, 2024 |
Exhibit 10.51 Fifteenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), an Ohio limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liability |
|
| March 14, 2024 |
Cardlytics Announces Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Cardlytics Announces Fourth Quarter and Full Year 2023 Financial Results Atlanta, GA – March 14, 2024 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the fourth quarter and full year ended December 31, 2023. Supplemental information is available on the Investor Relations section of the Cardlytics website at http://ir.cardlytics. |
|
| March 14, 2024 |
2023 Bonus Plan of the Registrant Exhibit 10.52 2023 Cardlytics Bonus Plan Overview The 2023 Cardlytics Bonus Plan (“Bonus Plan”) outlines certain financial benefits, in the form of cash bonus payments, that may be awarded to employees for helping Cardlytics, Inc. (“Company”) reach its corporate goals. The Bonus Plan applies to all employees of the Company and its subsidiaries who are not on commission plans, except for Entertainm |
|
| March 14, 2024 |
Exhibit 10.48 Assumption Agreement and Ninth Amendment to Loan and Security Agreement Existing Borrower: Cardlytics, Inc., a Delaware corporation (“Parent”) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company Additional Borrower: AFIN Intermediate Holdings, Inc. a Delaware corporation 675 Ponce de Leon Ave., Ste 600, Atlanta, GA 30308 Additional B |
|
| March 14, 2024 |
Amended Non-Employee Director Compensation Plan Exhibit 10.53 Non-Employee Director Compensation Policy As Amended and Restated October 26, 2023 Each member of the Board of Directors (the “Board”) of Cardlytics, Inc. (the “Company”) who is a non- employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation Poli |
|
| March 14, 2024 |
earningssdxq42023x31420 CARDLYTICS Q4 2023 Earnings Presentation March 14, 2024 Disclaimer This presentation includes forward-looking statements. |
|
| March 14, 2024 |
Amended and Restated Policy for Recoupment of Incentive Compensation, adopted on October 2, 2023 Exhibit 97.1 CARDLYTICS, INC. Amended and Restated Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Cardlytics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Amended and Restated Incentive Compe |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 CARDLYTICS, INC. |
|
| February 14, 2024 |
SC 13G/A 1 cdlxa221424.htm 683 CAPITAL MANAGEMENT, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14161W105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Stat |
|
| February 13, 2024 |
CDLX / Cardlytics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0530-cardlyticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Cardlytics Inc Title of Class of Securities: Common Stock CUSIP Number: 14161W105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the ru |
|
| February 7, 2024 |
CARDLYTICS, INC. 675 Ponce de Leon Avenue NE, Suite 4100 Atlanta, Georgia 30308 (888) 798-5802 CARDLYTICS, INC. 675 Ponce de Leon Avenue NE, Suite 4100 Atlanta, Georgia 30308 (888) 798-5802 February 7, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Re: Cardlytics, Inc. Registration Statement on Form S-3 File No. 333-276738 Ladies and Gentlemen: In accordance with Rule 461 under the Securit |
|
| February 6, 2024 |
Mark Ballantyne +1 (703) 456-8084 [email protected] Via EDGAR February 6, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: Jan Woo Kathleen Krebs Re: Cardlytics, Inc. Registration Statement on Form S-3 Filed January 29, 2024 File No. 333-276738 Ladies and Gentlemen: On behalf of C |
|
| February 6, 2024 |
As filed with the Securities and Exchange Commission on February 6, 2024 S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 6, 2024 Registration No. |
|
| February 2, 2024 |
United States securities and exchange commission logo February 2, 2024 Karim Temsamani Chief Executive Officer Cardlytics, Inc. |
|
| January 29, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 CARDLYTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CARDLYTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Cardlytics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under t |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Common Stock, par value $0.0001 per share 2018 Equity In |
|
| January 29, 2024 |
EX-4.3 Exhibit 4.3 CARDLYTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Sec |
|
| January 29, 2024 |
Cardlytics Announces Successful Resolution of SRS Dispute and Preliminary Fourth Quarter 2023 Results Expects Preliminary Results to Allow Extension of Credit Facility Maturity Date to April 2025 ATLANTA, Jan. |
|
| January 29, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 Exhibit 4.5 CARDLYTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CARDLYTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Cardlytics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws o |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 CARDLYTICS, INC. |
|
| January 29, 2024 |
Exhibit 10.1 Settlement Agreement WHEREAS, as of April 12, 2021, Cardlytics, Inc. (“Cardlytics”), Mr. T Merger Sub, Inc., and Bridg, Inc. (“Bridg”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Cardlytics acquired Bridg; WHEREAS, Shareholder Representative Services LLC (the “Stockholder Representative”) is a party to the Merger Agreement solely in its capa |
|
| January 29, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 CARDLYTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CARDLYTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Cardlytics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under t |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CARDLYTICS, INC. |
|
| January 26, 2024 |
CDLX / Cardlytics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us14161w1053012624.txt us14161w1053012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) CARDLYTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 14161W105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 CARDLYTICS, INC. |
|
| January 2, 2024 |
Cardlytics Appoints Two New Members to its Board of Directors Cardlytics Appoints Two New Members to its Board of Directors ATLANTA, GA – January 2, 2024 – Cardlytics, Inc. |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 CARDLYTICS, INC. |
|
| November 8, 2023 |
Cardlytics Announces Third Quarter 2023 Financial Results Exhibit 99.1 Cardlytics Announces Third Quarter 2023 Financial Results Atlanta, GA – November 8, 2023 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2023. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. "We are gathering speed |
|
| November 8, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 CARDLYTICS, INC. |
|
| November 8, 2023 |
CARDLYTICS Q3 2023 Earnings Presentation November 8, 2023 Disclaimer This presentation includes forward-looking statements. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 CARDLYTICS, INC. |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 CARDLYTICS, INC. |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 14161W105 (CUSIP Number) CLIFFORD SOSIN CAS INVESTMENT |
|
| September 19, 2023 |
Cardlytics Appoints Alex Mishurov to its Board of Directors Exhibit 99.1 Cardlytics Appoints Alex Mishurov to its Board of Directors ATLANTA, GA – September 19, 2023 – Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks’ digital channels, is excited to announce the appointment of Alex Mishurov as an independent member of its Board of Directors. Mishurov will serve on the Board’s Compensation Committee, Nominating and Corporate Governance Comm |
|
| September 19, 2023 |
Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of September 19, 2023 by and among Cardlytics, Inc., a Delaware corporation (the “Company”), on the one hand, and those certain investors set forth on Exhibit A hereto (collectively, the “Investors”), on the other hand. The Company and the Investors are referred to in this Agreement as the |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 CARDLYTICS, INC. |
|
| September 6, 2023 |
Finance Veteran Scott A. Hill appointed to Cardlytics Board of Directors Finance Veteran Scott A. Hill appointed to Cardlytics Board of Directors ATLANTA, GA – September 6, 2023 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, is excited to announce the appointment of Scott A. Hill to its Board of Directors. In connection with his appointment to the Board of Directors, Hill was also appointed to the Board’s Audit Committee. Hill brings over 30 years o |
|
| August 1, 2023 |
Offer Letter Agreement between Alexis DeSieno and the Registrant dated June 20, 2023 Exhibit 10.2 June 16, 2023 Alexis DeSieno, Chief Financial Officer Start Date: August 14, 2023 Alexis, I am pleased to present you with Cardlytics’ (“Company”) offer to employ you as Chief Financial Officer, reporting to Karim Temsamani, Chief Executive Officer. Your target start date will be August 14, 2023. We are excited to bring you on board and believe you will contribute significantly to the |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| August 1, 2023 |
earningssdxq22023x07312 CARDLYTICS Q2 2023 Earnings Presentation August 1, 2023 Disclaimer This presentation includes forward-looking statements. |
|
| August 1, 2023 |
Cardlytics Announces Second Quarter 2023 Financial Results Exhibit 99.1 Cardlytics Announces Second Quarter 2023 Financial Results Atlanta, GA – August 1, 2023 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the second quarter ended June 30, 2023. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. "Our results this quarter are |
|
| August 1, 2023 |
Separation Pay Agreement between Alexis DeSieno and the Registrant, dated July 13, 2023. Exhibit 10.3 SEPARATION PAY AGREEMENT This Separation Pay Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”) and Alexis DeSieno (“You” or “Your”) (collectively, the “Parties”), is entered into and effective as of August 14, 2023 (the “Effective Date”). WHEREAS, The Company has offered to employ You; WHEREAS, the Company and You have agreed to certain payment obligations up |
|
| August 1, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO SCHEDULE #1 OF THE MASTER AGREEMENT This Third Amendment (“Third Amendment”) to Schedule #1 is entered into as of June 1, 2023 (the “Third Amendment Effective Date”) by and between CARDLYTICS, INC. (“Supplier” or “Cardlytics”) and JPMORGAN CHASE BANK, NATIONAL ASSOCIATION (“JPMC”). WHEREAS, JPMC and Supplier previously entered into that certain Schedule #1 on May 4, |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 CARDLYTICS, INC. |
|
| July 18, 2023 |
Amendment No. 2 to 2022 Inducement Plan Exhibit 4.8 AMENDMENT TO CARDLYTICS, INC. 2022 INDUCEMENT PLAN A. Cardlytics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2022 Inducement Plan (the “Plan”); B. The Plan currently provides for 1,850,000 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now wishes to amend the Plan to increase th |
|
| July 18, 2023 |
As filed with the Securities and Exchange Commission on July 18, 2023 Registration No. |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 CARDLYTICS, INC. |
|
| July 18, 2023 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate-Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per shar |
|
| July 18, 2023 |
Cardlytics Appoints New Chief Financial Officer Exhibit 99.1 Cardlytics Appoints New Chief Financial Officer ATLANTA, GA – July 18, 2023 – Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in bank’s digital channels, is pleased to announce the appointment of Alexis DeSieno as Chief Financial Officer. DeSieno brings a wealth of experience and expertise in finance and data analytics, and will play a vital role in profitably growing Cardlyt |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2023 CARDLYTICS, INC. |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 CARDLYTICS, INC. |
|
| June 23, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.0001, of Cardlytics, Inc. This Joint Filing Agreement shall be |
|
| June 23, 2023 |
CDLX / Cardlytics Inc / CAS Investment Partners, LLC - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 14161W105 (CUSIP Number) CLIFFORD SOSIN CAS INVESTMENT |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 CARDLYTICS, INC. |
|
| May 4, 2023 |
Cardlytics Announces First Quarter 2023 Financial Results Exhibit 99.1 Cardlytics Announces First Quarter 2023 Financial Results Atlanta, GA – May 4, 2023 – Cardlytics Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2023. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. "We are excited to move past the d |
|
| May 4, 2023 |
Exhibit 10.5 Thirteenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liabil |
|
| May 4, 2023 |
Transition Letter Agreement by and between Andrew Christiansen and Cardlytics, Inc. Exhibit 10.3 Transition Agreement This Transition Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”) and Andy Christiansen (“You” or “Your”) (collectively the “Parties”) is entered into and effective as of March 17, 2023 (the “Effective Date”). 1.Termination of Separation Agreement. As of the Effective Date, the Parties acknowledge and agree that the Amended and Restated S |
|
| May 4, 2023 |
Exhibit 10.4 AMENDMENT NO. 2 TO OFFICE LEASE AGREEMENT THIS AMENDMENT NO. 2 TO OFFICE LEASE AGREEMENT (this “Amendment”) is made as of the 3rd day of April, 2023, by and between JAMESTOWN Ponce City Market, L.P., a Delaware limited partnership (“Landlord”) and CARDLYTICS, INC., a Delaware corporation (“Tenant”). RECITALS: Landlord and Tenant entered into that certain Office Lease dated August 5, 2 |
|
| May 4, 2023 |
earningssdxq12023x05042 CARDLYTICS Q1 2023 Earnings Presentation May 4, 2023 Disclaimer This presentation includes forward-looking statements. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 CARDLYTICS, INC. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 CARDLYTICS, INC. |
|
| April 27, 2023 |
As filed with the Securities and Exchange Commission on April 26, 2023 As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTAIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Materials Pursuant to 240. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 4, 2023 |
Cardlytics Announces Updated Guidance for First Quarter 2023 Financial Results Exhibit 99.1 Cardlytics Announces Updated Guidance for First Quarter 2023 Financial Results Atlanta, GA – April 4, 2023 - Cardlytics, Inc., (NASDAQ: CDLX), a digital advertising platform, today announced updated guidance for the first quarter ended March 31, 2023. First Quarter 2023 Updated Guidance Cardlytics anticipates billings, revenue, adjusted contribution and adjusted EBITDA to be in the fo |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 CARDLYTICS, INC. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 CARDLYTICS, INC. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 CARDLYTICS, INC. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 CARDLYTICS, INC. |
|
| March 1, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Cardlytics, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Exhibit 4.6 Cardlytics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Cardlytics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing un |
|
| March 1, 2023 |
Exhibit 10.45 AMENDMENT TO CARDLYTICS, INC. 2022 INDUCEMENT PLAN A. Cardlytics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2022 Inducement Plan (the “Plan”); B. The Plan currently provides for 1,500,000 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now wishes to amend the Plan to increase |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
Power of Attorney (see signature). As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
Cardlytics Announces Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 Cardlytics Announces Fourth Quarter and Fiscal Year 2022 Financial Results Atlanta, GA – March 1, 2023 – Cardlytics, Inc., (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022. Supplemental information is available on the Investor Relations section of the Cardlytics' website at http://ir.cardly |
|
| March 1, 2023 |
Severance Agreement between Amit Gupta and Cardlytics, Inc. Exhibit 10.43 SEVERANCE AGREEMENT This Severance Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”), and Amit Gupta (“You” or “Your”) (collectively, the “Parties”), is entered into and effective as of January 23, 2023 (the “Effective Date”). WHEREAS, the Company and You have agreed to certain payment obligations upon termination of Your employment Without Cause (as defined |
|
| March 1, 2023 |
Exhibit 10.44 Twelfth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liabilit |
|
| March 1, 2023 |
2022 Bonus Plan of the Registrant Exhibit 10.46 2022 Bonus Plan Overview The Cardlytics Bonus Plan (“Bonus Plan”) rewards employees for helping Cardlytics (“Company”) reach our corporate goals and for employees’ personal performance. This document provides details on the 2022 Bonus Plan. If you have additional questions, please speak with your manager or People Operations. Bonus Potential Your bonus potential is a percentage (%) o |
|
| March 1, 2023 |
Exhibit 10.41 Eleventh Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (“Parent”) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liabili |
|
| March 1, 2023 |
Offer Letter Agreement between Amit Gupta and Cardlytics, Inc. Exhibit 10.42 December 16, 2022 Amit Gupta Amit, I am pleased to present you with Cardlytics’ (“Company”) offer to employ you as Chief Operating Officer, reporting to Karim Temsamani, Chief Executive Officer. Your target start date will be January 23, 2023. We are excited to bring you on board and believe you will contribute significantly to the success of our organization. The following terms wil |
|
| March 1, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 CARDLYTICS, INC. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Exhibit 4.5 Cardlytics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Cardlytics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the l |
|
| March 1, 2023 |
Exhibit 107 Filing Fee Tables Form S-3 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, par value $0.000 |
|
| March 1, 2023 |
earningssdxq42022x20230 CARDLYTICS Q4 2022 Earnings Presentation March 1, 2023 Disclaimer This presentation includes forward-looking statements. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| February 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14161W105 (CUSIP Number) December 31, 2022 (Date of Eve |
|
| February 14, 2023 |
EX-1 2 ex1.htm CAS Investment Partners, LLC SC 13G/A Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional join |
|
| February 14, 2023 |
CDLX / Cardlytics Inc / CAS Investment Partners, LLC - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 cdlx-sch13ga123122.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Cardlytics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14161W105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 9, 2023 |
CDLX / Cardlytics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Cardlytics Inc. Title of Class of Securities: Common Stock CUSIP Number: 14161W105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 7, 2023 |
CDLX / Cardlytics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us14161w1053020723.txt us14161w1053020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CARDLYTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 14161W105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 23, 2023 |
As filed with the Securities and Exchange Commission on January 23, 2023 Registration No. |
|
| January 23, 2023 |
Cardlytics Appoints Amit Gupta as Chief Operating Officer Exhibit 99.1 Cardlytics Appoints Amit Gupta as Chief Operating Officer ATLANTA, GA – January 23, 2022 – Cardlytics (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced the appointment of Amit Gupta as its Chief Operating Officer, reporting directly to Karim Temsamani, Chief Executive Officer. Effective today, Gupta will lead Cardlytics’ overall operations, strategy, |
|
| January 23, 2023 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Common Stock, par value $0.0001 per share 2018 Equity In |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 CARDLYTICS, INC. |
|
| December 9, 2022 |
CDLX / Cardlytics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Cardlytics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14161W105 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 CARDLYTICS, INC. |
|
| November 18, 2022 |
Exhibit 10.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG CARDLYTICS, INC., MR. T MERGER SUB, INC., BRIDG, INC., AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS STOCKHOLDER REPRESENTATIVE April 12, 2021 TABLE OF CONTENTS Page Article 1 THE MERGER 2 1.1 Merger 2 1.2 Effective Time 2 1.3 Effects of the Merger 2 1.4 Closing; Closing Deliverables. 2 1.5 Certificate of Incorporation and Bylaws of Survivin |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 CARDLYTICS, INC. |
|
| November 14, 2022 |
Resignation and Release Agreement between Scott Grimes and Cardlytics, Inc. Exhibit 10.2 RESIGNATION AND RELEASE AGREEMENT THIS AGREEMENT (the ?Agreement?) is entered into as November 11, 2022 (?Effective Date?) by and between Cardlytics, Inc. (the ?Company?) and Scott Grimes (?Director?). Together, the Company and Director may be referred to hereinafter as the ?Parties.? WHEREAS, Director is currently the Executive Chairman of the Board of Directors (the ?Board?) of the |
|
| November 14, 2022 |
Resignation and Release Agreement between Lynne Laube and Cardlytics, Inc. Exhibit 10.1 RESIGNATION AND RELEASE AGREEMENT THIS AGREEMENT (the ?Agreement?) is entered into as of November 11, 2022 (?Effective Date?) by and between Cardlytics, Inc. (the ?Company?) and Lynne Laube (?Director?). Together, the Company and Director may be referred to hereinafter as the ?Parties.? WHEREAS, Director currently serves on the Board of Directors (the ?Board?) of the Company and as an |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| November 1, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 CARDLYTICS, INC. |
|
| November 1, 2022 |
Transition Letter Agreement between Lynne M. Laube and Cardlytics, Inc. Exhibit 10.1 Transition Agreement This Transition Agreement (the ?Agreement?), by and between Cardlytics, Inc. (the ?Company?) and Lynne Laube (?You? or ?Your?) (collectively the ?Parties?), is entered into and effective as of July 18, 2022 (the ?Effective Date?). 1.Termination of Separation Agreement. As of the Effective Date, the Parties acknowledge and agree that the Amended and Restated Separa |
|
| November 1, 2022 |
Severance Agreement between Karim Temsamani and Cardlytics, Inc. Exhibit 10.3 SEVERANCE AGREEMENT This Severance Agreement (the ?Agreement?) by and between Cardlytics, Inc. (the ?Company?), and Karim Temsamani (?You? or ?Your?) (collectively, the ?Parties?), is entered into and effective as of September 1, 2022 (the ?Effective Date?). WHEREAS, the Company and You have agreed to certain payment obligations upon termination of Your employment Without Cause (as de |
|
| November 1, 2022 |
CARDLYTICS Q3 2022 Earnings Presentation November 1, 2022 Disclaimer This presentation includes forward-looking statements. |
|
| November 1, 2022 |
Offer Letter Agreement between Karim Temsamani and Cardlytics, Inc. Exhibit 10.2 July 18, 2022 Karim Temsamani Karim, I am pleased to present you with Cardlytics? (?Company?) offer to employ you as Chief Executive Officer and appoint you to the Board of Directors. We are excited to bring you on board and believe you will lead the success of our growing organization. The following terms will serve as your compensation package, in accordance with the Company's estab |
|
| November 1, 2022 |
Severance Agreement between Nick Lynton and Cardlytics, Inc. Exhibit 10.4 AMENDED AND RESTATED SEPARATION PAY AGREEMENT This Separation Pay Agreement (the ?Agreement?) by and between Cardlytics, Inc. (the ?Company?), and Nick Lynton (?You? or ?Your?) (collectively, the ?Parties?), is entered into and effective as of August 8, 2022 (the ?Effective Date?). WHEREAS, You are currently employed by the Company; WHEREAS, the Company and You have agreed to certain |
|
| November 1, 2022 |
Cardlytics Announces Third Quarter 2022 Financial Results Exhibit 99.1 Cardlytics Announces Third Quarter 2022 Financial Results Atlanta, GA ? November 1, 2022 ? Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2022. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. ?We delivered solid doub |
|
| September 9, 2022 |
CDLX / Cardlytics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Cardlytics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14161W105 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| August 26, 2022 |
Exhibit 107 Filing Fee Tables Form S-8 (Form Type) CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Common Stock, par value $0.0001 per share 2022 Inducemen |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38386 CARDLYTICS, INC. |
|
| August 2, 2022 |
Cardlytics Announces Second Quarter 2022 Financial Results Exhibit 99.1 Cardlytics Announces Second Quarter 2022 Financial Results Atlanta, GA – August 2, 2022 – Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the second quarter ended June 30, 2022. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. “I am pleased with our growth |
|
| August 2, 2022 |
CARDLYTICS Q2 2022 Earnings Presentation August 2, 2022 Disclaimer This presentation includes forward-looking statements. |
|
| August 2, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 CARDLYTICS, INC. |
|
| August 2, 2022 |
Exhibit 10.3 Statement of Work Contract ID Number: Statement of Work (SOW) Cover Sheet BANA SOW Number Vendor SOW Number Not applicable BANA Master Agreement Number CW1649578 Effective Date Upon date of last Signature Expiration Date 07-31-2025 Vendor Name Cardlytics, Inc. Vendor Contact Name [***] Vendor Contact Phone Number [***] Vendor Contact Email Address [***] Vendor Contact Mailing Address |
|
| August 2, 2022 |
Exhibit 10.2 General Services Agreement Contract Title: General Services Agreement Number: CW1649578 Vendor Name: Cardlytics, Inc. Effective Date: Upon date of last signature Vendor Address: 675 Ponce de Leon Ave., Suite 6000 Atlanta, GA 30308 Expiration Date: July 31, 2025 Vendor Telephone: 888-798-5802 - Proprietary & Confidential Table of Contents - 1 Rev 10/2020 Certain information has been ex |
|
| August 2, 2022 |
Form of Transition Agreement by and between the Registrant and and Kirk L. Somers Exhibit 10.1 Transition Agreement This Transition Agreement (the “Agreement”), by and between Cardlytics, Inc. (the “Company”) and Kirk Somers (“You” or “Your”) (collectively the “Parties”), is entered into and effective as of June 20, 2022 (the “Effective Date”). 1.Termination of Separation Agreement. As of the Effective Date, the Parties acknowledge and agree that the Amended and Restated Separa |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 CARDLYTICS, INC. |
|
| July 21, 2022 |
CDLX / Cardlytics Inc / 683 Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Cardlytics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14161W105 (CUSIP Number) July 11, 2022 (Date of Event wh |
|
| July 20, 2022 |
Form of restricted stock unit grant notice and agreement under 2022 Inducement Plan Exhibit 10.3 Cardlytics, Inc. Restricted Stock Unit Grant Notice (2022 Inducement Plan) Cardlytics, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to all of the terms and conditions |
|
| July 20, 2022 |
Exhibit 10.1 Cardlytics, Inc. 2022 Inducement Plan Adopted by the Board of Directors: July 18, 2022 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under NASDAQ IM 5635-1. A per |
|
| July 20, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 CARDLYTICS, INC. |
|
| July 20, 2022 |
Form of option grant notice and agreement under 2022 Inducement Plan Exhibit 10.2 Cardlytics, Inc. Stock Option Grant Notice (2022 Inducement Plan) Cardlytics, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Opt |
|
| July 20, 2022 |
Exhibit 99.1 Cardlytics Appoints Karim Temsamani Chief Executive Officer Lynne Laube to Retire, Serve as Strategic Advisor During Transition ATLANTA, GA ? July 20, 2022 ? Cardlytics, (NASDAQ: CDLX), an advertising platform in banks? digital channels, today announced that its Board of Directors has named Karim Temsamani as Chief Executive Officer of the company, effective September 1, 2022. Temsama |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 CARDLYTICS, INC. |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 CARDLYTICS, INC. |
|
| June 3, 2022 |
CDLX / Cardlytics Inc / JPMORGAN CHASE & CO - FILING CARDLYTICS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* CARDLYTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 14161W105 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| May 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 CARDLYTICS, INC. |
|
| May 2, 2022 |
Cardlytics Announces First Quarter 2022 Financial Results Exhibit 99.1 Cardlytics Announces First Quarter 2022 Financial Results Atlanta, GA ? May 2, 2022 ? Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2022. Supplemental information is available on the Investor Relations section of Cardlytics' website at http://ir.cardlytics.com/. ?We had our largest Q1 ever and d |
|
| May 2, 2022 |
Exhibit 10.1 Tenth Amendment to Loan and Security Agreement Borrower: (1) Cardlytics, Inc., a Delaware corporation (?Parent?) (2) Dosh Holdings LLC (formerly known as BSpears Merger Sub II, LLC), a Delaware limited liability company (3) AFIN Intermediate Holdings, Inc. a Delaware corporation (4) AFIN Holdings Inc., a Delaware corporation (5) HSP EPI Acquisition, LLC, a Delaware limited liability c |
|
| May 2, 2022 |
CARDLYTICS Q1 2022 Earnings Presentation May 2, 2022 Disclaimer This presentation includes forward-looking statements. |
